NE 0080

Drug Profile

NE 0080

Alternative Names: NE 1327

Latest Information Update: 20 May 2002

Price : $50

At a glance

  • Originator Neose Technologies
  • Class Antibacterials; Antiulcers
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Helicobacter infections

Most Recent Events

  • 20 May 2002 Discontinued - Phase-II for Helicobacter infections in Europe (PO)
  • 20 May 2002 Discontinued - Phase-II for Helicobacter infections in USA (PO)
  • 07 Jul 1999 Phase-II clinical trials for Helicobacter infections in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top